Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil‐mimic formulation
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2017.08.030
Abstract: &NA; Due to the severe cardiotoxicity of doxorubicin, its usage is limited. This shortcoming could be overcome by modifying pharmacokinetics of the drugs via preparation of various nanoplatforms. Doxil, a well‐known FDA‐approved nanoplatform of doxorubicin… read more here.
Keywords: polymersomal formulation; doxil mimic; formulation; formulation doxorubicin ... See more keywords